Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 May;88(1):19-25.
doi: 10.1007/s11060-008-9536-2. Epub 2008 Feb 6.

Expression of TLR9 within human glioblastoma

Yuxia Meng  1 , Michèle Kujas, Yannick Marie, Sophie Paris, Joëlle Thillet, Jean-Yves Delattre, Antoine F Carpentier
Affiliations

Expression of TLR9 within human glioblastoma

Yuxia Meng et al. J Neurooncol. 2008 May.

Abstract

Immunostimulating oligonucleotides containing CpG motifs (CpG-ODN) have shown promising antitumor activity in preclinical glioma models. CpG motifs are specifically recognized by the Toll-like receptor 9 (TLR9), mainly expressed in plasmacytoid dendritic cells (pDCs) and B cells. Expression of TLR9 within human glioma samples has not been investigated. As CpG-ODN is currently under clinical trials in glioma patients, we investigated whether TLR9 is expressed at the RNA levels in a series of 37 human glioblastomas (GBM) by quantitative PCR. TLR9 expression was detected at variable levels, which might suggest that some patients are more likely to benefit from treatment with CpG-ODN than others. No significant relationships between TLR9 expression and age, sex, tumor location, lymphocytes infiltration, oligodendroglial components or survival were found. TLR9 is unlikely to be expressed by tumor cells as no TLR9 expression was detected in pure human GBM xenografts. Immunocytochemistry studies showed TLR9 expression in some macrophages/microglial cells. The expression of TLR9 within human GBM strengthens the rationale for the utilization of CpG-ODN in this disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Curr Oncol Rep. 2004 Mar;6(2):88-95 - PubMed
    1. J Neuropathol Exp Neurol. 2002 Nov;61(11):1013-21 - PubMed
    1. Cancer Res. 2004 Jul 1;64(13):4648-53 - PubMed
    1. J Immunol Methods. 2005 May;300(1-2):93-9 - PubMed
    1. Lancet. 2003 Jan 25;361(9354):323-31 - PubMed

Publication types

MeSH terms